Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37


Interaction between TLR9-CpG-ODNs and HBV virions leads to entry inhibition in hepatocytes and reduction of IFNα production by pDC.

Aillot L, Bonnin M, Ait-Goughoulte M, Bendriss-Vermare N, Maadadi S, Dimier L, Subic M, Scholtes C, Najera I, Zoulim F, Lucifora J, Durantel D.

Antimicrob Agents Chemother. 2018 Feb 12. pii: AAC.01741-17. doi: 10.1128/AAC.01741-17. [Epub ahead of print]


Genetic alterations and tumor immune attack in Yo paraneoplastic cerebellar degeneration.

Small M, Treilleux I, Couillault C, Pissaloux D, Picard G, Paindavoine S, Attignon V, Wang Q, Rogemond V, Lay S, Ray-Coquard I, Pfisterer J, Joly F, Du Bois A, Psimaras D, Bendriss-Vermare N, Caux C, Dubois B, Honnorat J, Desestret V.

Acta Neuropathol. 2018 Jan 3. doi: 10.1007/s00401-017-1802-y. [Epub ahead of print]


BAD-LAMP controls TLR9 trafficking and signalling in human plasmacytoid dendritic cells.

Combes A, Camosseto V, N'Guessan P, Argüello RJ, Mussard J, Caux C, Bendriss-Vermare N, Pierre P, Gatti E.

Nat Commun. 2017 Oct 13;8(1):913. doi: 10.1038/s41467-017-00695-1.


[Cancer immunotherapy via systemic RNA delivery to dendritic cells].

Richaud M, Bendriss-Vermare N.

Med Sci (Paris). 2017 Oct;33(10):852-856. doi: 10.1051/medsci/20173310013. Epub 2017 Oct 10. French. No abstract available.


The immune microenvironment of HPV-negative oral squamous cell carcinoma from never-smokers and never-drinkers patients suggests higher clinical benefit of IDO1 and PD1/PD-L1 blockade.

Foy JP, Bertolus C, Michallet MC, Deneuve S, Incitti R, Bendriss-Vermare N, Albaret MA, Ortiz-Cuaran S, Thomas E, Colombe A, Py C, Gadot N, Michot JP, Fayette J, Viari A, Van den Eynde B, Goudot P, Devouassoux-Shisheboran M, Puisieux A, Caux C, Zrounba P, Lantuejoul S, Saintigny P.

Ann Oncol. 2017 Aug 1;28(8):1934-1941. doi: 10.1093/annonc/mdx210.


Cross Talk between Inhibitory Immunoreceptor Tyrosine-Based Activation Motif-Signaling and Toll-Like Receptor Pathways in Macrophages and Dendritic Cells.

Hirsch I, Janovec V, Stranska R, Bendriss-Vermare N.

Front Immunol. 2017 Apr 7;8:394. doi: 10.3389/fimmu.2017.00394. eCollection 2017. Review.


A Milestone Review on How Macrophages Affect Tumor Growth.

Caux C, Ramos RN, Prendergast GC, Bendriss-Vermare N, Ménétrier-Caux C.

Cancer Res. 2016 Nov 15;76(22):6439-6442. doi: 10.1158/0008-5472.CAN-16-2631. No abstract available.


A novel regulation of PD-1 ligands on mesenchymal stromal cells through MMP-mediated proteolytic cleavage.

Dezutter-Dambuyant C, Durand I, Alberti L, Bendriss-Vermare N, Valladeau-Guilemond J, Duc A, Magron A, Morel AP, Sisirak V, Rodriguez C, Cox D, Olive D, Caux C.

Oncoimmunology. 2015 Oct 29;5(3):e1091146. eCollection 2016 Mar.


Plasmacytoid dendritic cells are dispensable for noninfectious intestinal IgA responses in vivo.

Moro-Sibilot L, This S, Blanc P, Sanlaville A, Sisirak V, Bardel E, Boschetti G, Bendriss-Vermare N, Defrance T, Dubois B, Kaiserlian D.

Eur J Immunol. 2016 Feb;46(2):354-9. doi: 10.1002/eji.201545977. Epub 2015 Nov 23.


pDC therapy induces recovery from EAE by recruiting endogenous pDC to sites of CNS inflammation.

Duraes FV, Lippens C, Steinbach K, Dubrot J, Brighouse D, Bendriss-Vermare N, Issazadeh-Navikas S, Merkler D, Hugues S.

J Autoimmun. 2016 Feb;67:8-18. doi: 10.1016/j.jaut.2015.08.014. Epub 2015 Sep 1.


Breast Cancer Cell-Derived GM-CSF Licenses Regulatory Th2 Induction by Plasmacytoid Predendritic Cells in Aggressive Disease Subtypes.

Ghirelli C, Reyal F, Jeanmougin M, Zollinger R, Sirven P, Michea P, Caux C, Bendriss-Vermare N, Donnadieu MH, Caly M, Fourchotte V, Vincent-Salomon A, Sigal-Zafrani B, Sastre-Garau X, Soumelis V.

Cancer Res. 2015 Jul 15;75(14):2775-87. doi: 10.1158/0008-5472.CAN-14-2386. Epub 2015 May 14.


TLR9 transcriptional regulation in response to double-stranded DNA viruses.

Zannetti C, Parroche P, Panaye M, Roblot G, Gruffat H, Manet E, Debaud AL, Plumas J, Vey N, Caux C, Bendriss-Vermare N, Hasan UA.

J Immunol. 2014 Oct 1;193(7):3398-408. doi: 10.4049/jimmunol.1400249. Epub 2014 Sep 5.


ICOS is associated with poor prognosis in breast cancer as it promotes the amplification of immunosuppressive CD4+ T cells by plasmacytoid dendritic cells.

Faget J, Sisirak V, Blay JY, Caux C, Bendriss-Vermare N, Ménétrier-Caux C.

Oncoimmunology. 2013 Mar 1;2(3):e23185.


Tumor promotion by intratumoral plasmacytoid dendritic cells is reversed by TLR7 ligand treatment.

Le Mercier I, Poujol D, Sanlaville A, Sisirak V, Gobert M, Durand I, Dubois B, Treilleux I, Marvel J, Vlach J, Blay JY, Bendriss-Vermare N, Caux C, Puisieux I, Goutagny N.

Cancer Res. 2013 Aug 1;73(15):4629-40. doi: 10.1158/0008-5472.CAN-12-3058. Epub 2013 May 30.


Breast cancer-derived transforming growth factor-β and tumor necrosis factor-α compromise interferon-α production by tumor-associated plasmacytoid dendritic cells.

Sisirak V, Vey N, Goutagny N, Renaudineau S, Malfroy M, Thys S, Treilleux I, Labidi-Galy SI, Bachelot T, Dezutter-Dambuyant C, Ménétrier-Caux C, Blay JY, Caux C, Bendriss-Vermare N.

Int J Cancer. 2013 Aug 1;133(3):771-8. doi: 10.1002/ijc.28072. Epub 2013 Mar 8.


ICOS-ligand expression on plasmacytoid dendritic cells supports breast cancer progression by promoting the accumulation of immunosuppressive CD4+ T cells.

Faget J, Bendriss-Vermare N, Gobert M, Durand I, Olive D, Biota C, Bachelot T, Treilleux I, Goddard-Leon S, Lavergne E, Chabaud S, Blay JY, Caux C, Ménétrier-Caux C.

Cancer Res. 2012 Dec 1;72(23):6130-41. doi: 10.1158/0008-5472.CAN-12-2409. Epub 2012 Oct 1.


Impaired IFN-α production by plasmacytoid dendritic cells favors regulatory T-cell expansion that may contribute to breast cancer progression.

Sisirak V, Faget J, Gobert M, Goutagny N, Vey N, Treilleux I, Renaudineau S, Poyet G, Labidi-Galy SI, Goddard-Leon S, Durand I, Le Mercier I, Bajard A, Bachelot T, Puisieux A, Puisieux I, Blay JY, Ménétrier-Caux C, Caux C, Bendriss-Vermare N.

Cancer Res. 2012 Oct 15;72(20):5188-97. doi: 10.1158/0008-5472.CAN-11-3468. Epub 2012 Jul 25.


Plasmacytoid dendritic cells infiltrating ovarian cancer are associated with poor prognosis.

Labidi-Galy SI, Treilleux I, Goddard-Leon S, Combes JD, Blay JY, Ray-Coquard I, Caux C, Bendriss-Vermare N.

Oncoimmunology. 2012 May 1;1(3):380-382.


Gene expression profiling identifies sST2 as an effector of ErbB2-driven breast carcinoma cell motility, associated with metastasis.

Gillibert-Duplantier J, Duthey B, Sisirak V, Salaün D, Gargi T, Trédan O, Finetti P, Bertucci F, Birnbaum D, Bendriss-Vermare N, Badache A.

Oncogene. 2012 Jul 26;31(30):3516-24. doi: 10.1038/onc.2011.525. Epub 2011 Nov 21.


CCR6/CCR10-mediated plasmacytoid dendritic cell recruitment to inflamed epithelia after instruction in lymphoid tissues.

Sisirak V, Vey N, Vanbervliet B, Duhen T, Puisieux I, Homey B, Bowman EP, Trinchieri G, Dubois B, Kaiserlian D, Lira SA, Puisieux A, Blay JY, Caux C, Bendriss-Vermare N.

Blood. 2011 Nov 10;118(19):5130-40. doi: 10.1182/blood-2010-07-295626. Epub 2011 Sep 21.


Quantitative and functional alterations of plasmacytoid dendritic cells contribute to immune tolerance in ovarian cancer.

Labidi-Galy SI, Sisirak V, Meeus P, Gobert M, Treilleux I, Bajard A, Combes JD, Faget J, Mithieux F, Cassignol A, Tredan O, Durand I, Ménétrier-Caux C, Caux C, Blay JY, Ray-Coquard I, Bendriss-Vermare N.

Cancer Res. 2011 Aug 15;71(16):5423-34. doi: 10.1158/0008-5472.CAN-11-0367. Epub 2011 Jun 22.


Prognostic value of the expression of C-Chemokine Receptor 6 and 7 and their ligands in non-metastatic breast cancer.

Cassier PA, Treilleux I, Bachelot T, Ray-Coquard I, Bendriss-Vermare N, Ménétrier-Caux C, Trédan O, Goddard-Léon S, Pin JJ, Mignotte H, Bathélémy-Dubois C, Caux C, Lebecque S, Blay JY.

BMC Cancer. 2011 May 30;11:213. doi: 10.1186/1471-2407-11-213.


Impaired Toll-like receptor 7 and 9 signaling: from chronic viral infections to cancer.

Hirsch I, Caux C, Hasan U, Bendriss-Vermare N, Olive D.

Trends Immunol. 2010 Oct;31(10):391-7. doi: 10.1016/ Epub 2010 Sep 9. Review.


Cancer cell expression of autotaxin controls bone metastasis formation in mouse through lysophosphatidic acid-dependent activation of osteoclasts.

David M, Wannecq E, Descotes F, Jansen S, Deux B, Ribeiro J, Serre CM, Grès S, Bendriss-Vermare N, Bollen M, Saez S, Aoki J, Saulnier-Blache JS, Clézardin P, Peyruchaud O.

PLoS One. 2010 Mar 17;5(3):e9741. doi: 10.1371/journal.pone.0009741.


Characterization of circulating dendritic cells in melanoma: role of CCR6 in plasmacytoid dendritic cell recruitment to the tumor.

Charles J, Di Domizio J, Salameire D, Bendriss-Vermare N, Aspord C, Muhammad R, Lefebvre C, Plumas J, Leccia MT, Chaperot L.

J Invest Dermatol. 2010 Jun;130(6):1646-56. doi: 10.1038/jid.2010.24. Epub 2010 Mar 11.


Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome.

Gobert M, Treilleux I, Bendriss-Vermare N, Bachelot T, Goddard-Leon S, Arfi V, Biota C, Doffin AC, Durand I, Olive D, Perez S, Pasqual N, Faure C, Ray-Coquard I, Puisieux A, Caux C, Blay JY, Ménétrier-Caux C.

Cancer Res. 2009 Mar 1;69(5):2000-9. doi: 10.1158/0008-5472.CAN-08-2360. Epub 2009 Feb 24.


Virus overrides the propensity of human CD40L-activated plasmacytoid dendritic cells to produce Th2 mediators through synergistic induction of IFN-{gamma} and Th1 chemokine production.

Bendriss-Vermare N, Burg S, Kanzler H, Chaperot L, Duhen T, de Bouteiller O, D'agostini M, Bridon JM, Durand I, Sederstrom JM, Chen W, Plumas J, Jacob MC, Liu YJ, Garrone P, Trinchieri G, Caux C, Brière F.

J Leukoc Biol. 2005 Oct;78(4):954-66. Epub 2005 Aug 4.


Dendritic cell infiltration and prognosis of early stage breast cancer.

Treilleux I, Blay JY, Bendriss-Vermare N, Ray-Coquard I, Bachelot T, Guastalla JP, Bremond A, Goddard S, Pin JJ, Barthelemy-Dubois C, Lebecque S.

Clin Cancer Res. 2004 Nov 15;10(22):7466-74.


CD4 lymphopenia as a risk factor for febrile neutropenia and early death after cytotoxic chemotherapy in adult patients with cancer.

Borg C, Ray-Coquard I, Philip I, Clapisson G, Bendriss-Vermare N, Menetrier-Caux C, Sebban C, Biron P, Blay JY.

Cancer. 2004 Dec 1;101(11):2675-80.


In situ leukemic plasmacytoid dendritic cells pattern of chemokine receptors expression and in vitro migratory response.

Bendriss-Vermare N, Chaperot L, Peoc'h M, Vanbervliet B, Jacob MC, Briere F, Bensa JC, Caux C, Plumas J.

Leukemia. 2004 Sep;18(9):1491-8.


Breast carcinoma cells promote the differentiation of CD34+ progenitors towards 2 different subpopulations of dendritic cells with CD1a(high)CD86(-)Langerin- and CD1a(+)CD86(+)Langerin+ phenotypes.

Thomachot MC, Bendriss-Vermare N, Massacrier C, Biota C, Treilleux I, Goddard S, Caux C, Bachelot T, Blay JY, Menetrier-Caux C.

Int J Cancer. 2004 Jul 10;110(5):710-20.


The inducible CXCR3 ligands control plasmacytoid dendritic cell responsiveness to the constitutive chemokine stromal cell-derived factor 1 (SDF-1)/CXCL12.

Vanbervliet B, Bendriss-Vermare N, Massacrier C, Homey B, de Bouteiller O, Brière F, Trinchieri G, Caux C.

J Exp Med. 2003 Sep 1;198(5):823-30.


Origin and filiation of human plasmacytoid dendritic cells.

Brière F, Bendriss-Vermare N, Delale T, Burg S, Corbet C, Rissoan MC, Chaperot L, Plumas J, Jacob MC, Trinchieri G, Bates EE.

Hum Immunol. 2002 Dec;63(12):1081-93. Review.


The transcription factor Spi-B is expressed in plasmacytoid DC precursors and inhibits T-, B-, and NK-cell development.

Schotte R, Rissoan MC, Bendriss-Vermare N, Bridon JM, Duhen T, Weijer K, Brière F, Spits H.

Blood. 2003 Feb 1;101(3):1015-23. Epub 2002 Sep 19.


Subtractive hybridization reveals the expression of immunoglobulin-like transcript 7, Eph-B1, granzyme B, and 3 novel transcripts in human plasmacytoid dendritic cells.

Rissoan MC, Duhen T, Bridon JM, Bendriss-Vermare N, Péronne C, de Saint Vis B, Brière F, Bates EE.

Blood. 2002 Nov 1;100(9):3295-303.


Human thymus contains IFN-alpha-producing CD11c(-), myeloid CD11c(+), and mature interdigitating dendritic cells.

Bendriss-Vermare N, Barthélémy C, Durand I, Bruand C, Dezutter-Dambuyant C, Moulian N, Berrih-Aknin S, Caux C, Trinchieri G, Brière F.

J Clin Invest. 2001 Apr;107(7):835-44. Erratum in: J Clin Invest 2001 Oct;108(8):1237.

Supplemental Content

Loading ...
Support Center